Saudi Arabia Cancer Immunotherapy Market Overview

Market Size in 2024: USD 1,201.9 Million

Market Size in 2033: USD 2,493.8 Million

Market Growth Rate 2025-2033: 8.45%

According to IMARC Group's latest research publication, "Saudi Arabia Cancer Immunotherapy Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033", The Saudi Arabia cancer immunotherapy market size reached USD 1,201.9 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 2,493.8 Million by 2033, exhibiting a growth rate (CAGR) of 8.45% during 2025-2033.

How AI is Reshaping the Future of Saudi Arabia Cancer Immunotherapy Market

• Revolutionizing Biomarker Discovery and Patient Selection: AI-powered machine learning algorithms are transforming immunotherapy effectiveness through predictive biomarker identification for immune checkpoint inhibitors, analyzing gene expression profiles and tumor microenvironment characteristics to enable personalized therapeutic approaches that improve patient response rates by 35-40% while reducing treatment costs and adverse effects in Saudi oncology centers.
• Enhancing Drug Discovery and Development: Advanced AI platforms are accelerating cancer immunotherapy drug development through automated analysis of molecular structures, protein interactions, and clinical trial data, reducing drug discovery timelines by 40-50% while supporting the Middle East AI in oncology market projected to reach USD 111.33 million in 2024 with a robust CAGR of 21.94% through 2033.
• Optimizing Treatment Response Prediction: Machine learning models utilizing radiographic imaging, PET scans, and CT analysis are revolutionizing immunotherapy response prediction by assessing lesion texture, shape, spatial heterogeneity, and metabolic activity, enabling clinicians to identify patients most likely to benefit from anti-PD1/PD-L1 therapies with 85-90% accuracy while preventing unnecessary treatments and associated healthcare costs.
• Facilitating Precision Immunotherapy Design: AI-driven platforms are enabling next-generation CAR-T cell therapy development through intelligent antigen target identification, CAR construct optimization, and patient-specific treatment customization, supporting Saudi Arabia's adoption of breakthrough therapies like KYMRIAH (tisagenlecleucel) and advancing the Kingdom's position as a regional leader in cellular immunotherapy with over USD 65 billion healthcare infrastructure investments.
• Improving Clinical Trial Design and Patient Matching: Natural language processing and AI algorithms are transforming clinical trial operations through automated patient recruitment, eligibility screening, and real-time adverse event monitoring, addressing the limited number of immunotherapy clinical trials in Saudi Arabia and supporting Vision 2030 objectives to establish the Kingdom as a hub for biomedical research and innovative cancer treatments.

Grab a sample PDF of this report: https://www.imarcgroup.com/saudi-arabia-cancer-immunotherapy-market/requestsample

Saudi Arabia Cancer Immunotherapy Market Trends & Drivers:

Saudi Arabia's cancer immunotherapy market is experiencing exceptional growth driven by the alarming rise in cancer incidence, with 27,885 new cases reported in 2020 and projections indicating a surge to 60,429 cases by 2040, representing a 116.7% increase. The Kingdom recorded 24,485 cancer incidences in 2018, with breast, colorectal, thyroid, and leukemia representing the highest malignancies, creating unprecedented demand for advanced immunotherapy treatments that offer superior efficacy and reduced side effects compared to conventional chemotherapy and radiation approaches.

Government-backed healthcare transformation initiatives under Vision 2030 are reshaping the oncology landscape, with Saudi Arabia investing over USD 65 billion in healthcare infrastructure development, including construction of specialized cancer centers and research facilities. The Saudi Food and Drug Authority (SFDA) has streamlined approval processes for new cancer medications, with five checkpoint inhibitors—Yervoy (ipilimumab), Opdivo (nivolumab), Keytruda (pembrolizumab), Tecentriq (atezolizumab), and Bavencio (avelumab)—receiving regulatory approval, while KYMRIAH (tisagenlecleucel) became the first CAR-T cell therapy licensed in the Kingdom, marking a milestone in cellular immunotherapy accessibility.

Strategic international partnerships are accelerating market development, with Kite, a Gilead Company, establishing local operations to support CAR-T cell therapy adoption and workforce development aligned with Vision 2030 objectives. In May 2025, ImmunityBio signed a strategic MOU with Saudi Arabia's Ministry of Investment, King Faisal Specialist Hospital & Research Centre (KFSHRC), and King Abdullah International Medical Research Center (KAIMRC) to introduce the FDA-approved Cancer BioShield platform powered by Anktiva® (nogapendekin alfa inbakicept), the world's first IL-15 superagonist to proliferate NK and T cells. The deployment of AI-powered diagnostic solutions, including Lunit INSIGHT CXR by Saudi Government and Seha Virtual Hospital in June 2025 for large-scale cancer screening, and Lunit's multi-year contract with SEHA for AI mammography analysis in March 2025, demonstrate the Kingdom's commitment to integrating cutting-edge technologies. The establishment of the Saudi Oncology Health Economics Expert Group (SHARP) by AstraZeneca and the Saudi Society of Clinical Pharmacy (SSCP) is creating cost-effective platforms for cancer patients, while positive clinical outcomes showing superior patient response to immunotherapy versus traditional chemotherapeutic regimens are driving adoption across hospitals, cancer research centers, and specialized clinics throughout Northern and Central, Western, Eastern, and Southern regions.

Saudi Arabia Cancer Immunotherapy Industry Segmentation:

The report has segmented the market into the following categories:

Therapy Type Insights:

• Monoclonal Antibodies
• Cancer Vaccines
• Checkpoint Inhibitors
• Immunomodulators
• Others

Application Insights:

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Melanoma
• Prostate Cancer
• Head and Neck Cancer
• Others

End User Insights:

• Hospitals
• Cancer Research Centers
• Clinics
• Others

Breakup by Region:

• Northern and Central Region
• Western Region
• Eastern Region
• Southern Region

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Recent News and Developments in Saudi Arabia Cancer Immunotherapy Market

• June 2025: Lunit's AI solution, Lunit INSIGHT CXR, was deployed by the Saudi Government and Seha Virtual Hospital for large-scale cancer screening, integrating AI-powered algorithms in cancer diagnostics to enhance early detection capabilities and support Vision 2030's healthcare transformation objectives.
• May 2025: ImmunityBio signed a strategic Memorandum of Understanding with Saudi Arabia's Ministry of Investment, King Faisal Specialist Hospital & Research Centre (KFSHRC), and King Abdullah International Medical Research Center (KAIMRC) to introduce the FDA-approved Cancer BioShield platform powered by Anktiva®, the world's first IL-15 superagonist, marking a paradigm shift in immune-restorative cancer therapies in the Middle East.
• March 2025: Lunit secured a multi-year contract with Abu Dhabi Health Services Company (SEHA) to deploy its AI-powered mammography analysis solution, Lunit INSIGHT MMG, demonstrating regional expansion of advanced cancer diagnostic technologies supporting early detection and immunotherapy patient selection across the GCC.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: [email protected]

Tel No:(D) +91 120 433 0800

United States: +1-201971-6302